These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17355112)

  • 1. 13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer--report of a pilot phase II study.
    Michael A; Hill M; Maraveyas A; Dalgleish A; Lofts F
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):150-3. PubMed ID: 17355112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.
    Ridwelski K; Fahlke J; Kuhn R; Hribaschek A; Kettner E; Greiner C; Florschuetz A; Manger T; Wilhelm G; Klein H; Hahnfeld S; Lippert H; Meyer F
    Eur J Surg Oncol; 2006 Apr; 32(3):297-302. PubMed ID: 16414235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.
    Xiros N; Papacostas P; Economopoulos T; Samelis G; Efstathiou E; Kastritis E; Kalofonos H; Onyenadum A; Skarlos D; Bamias A; Gogas H; Bafaloukos D; Samantas E; Kosmidis P
    Ann Oncol; 2005 May; 16(5):773-9. PubMed ID: 15802284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine therapy in patients with advanced pancreatic cancer.
    Min YJ; Joo KR; Park NH; Yun TK; Nah YW; Nam CW; Park JH
    Korean J Intern Med; 2002 Dec; 17(4):259-62. PubMed ID: 12647642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
    Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
    Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
    Fortune BE; Li X; Kosuri KV; Weatherby LM; Thomas JP; Bekaii-Saab TS
    Oncology; 2009; 76(5):333-7. PubMed ID: 19307739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
    Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
    Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
    Franciosi V; Barbieri R; Aitini E; Vasini G; Cacciani GC; Capra R; Camisa R; Cascinu S
    Lung Cancer; 2003 Jul; 41(1):101-6. PubMed ID: 12826318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
    Saito K; Isayama H; Nakai Y; Takahara N; Ishigaki K; Takeda T; Hakuta R; Saito T; Uchino R; Kishikawa T; Hamada T; Mizuno S; Sasaki T; Kogure H; Matsubara S; Yamamoto N; Ijichi H; Tateishi K; Tada M; Koike K
    Invest New Drugs; 2019 Apr; 37(2):338-344. PubMed ID: 30411217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer.
    Takahashi Y; Mai M; Sawabu N; Nishioka K
    Pancreas; 2005 Apr; 30(3):206-10. PubMed ID: 15782095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.
    Lee KH; Kim MK; Kim YH; Ryoo BY; Lim HY; Song HS; Kim HK; Lee MA; Im SA; Chang HM; Cho JY; Zang DY; Kim BS; Kim JS
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):317-25. PubMed ID: 19034448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
    Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
    Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Boeck S; Wilkowski R; Bruns CJ; Issels RD; Schulz C; Moosmann N; Laessig D; Haas M; Golf A; Heinemann V
    Oncology; 2007; 73(3-4):221-7. PubMed ID: 18424886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
    Neri B; Cipriani G; Grifoni R; Molinara E; Pantaleo P; Rangan S; Vannini A; Tonelli P; Valeri A; Pantalone D; Taddei A; Bechi P
    Oncol Res; 2009; 17(11-12):559-64. PubMed ID: 19806786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
    Abou-Alfa GK; Letourneau R; Harker G; Modiano M; Hurwitz H; Tchekmedyian NS; Feit K; Ackerman J; De Jager RL; Eckhardt SG; O'Reilly EM
    J Clin Oncol; 2006 Sep; 24(27):4441-7. PubMed ID: 16983112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.
    Neubauer MA; Reynolds CH; Joppert MG; Whitaker T; Ghaddar H; Marsland TA; Asmar L
    Clin Lung Cancer; 2005 Jan; 6(4):245-9. PubMed ID: 15694017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.